Memorial Sloan Kettering Cancer Center

🇺🇸United States

Country: 🇺🇸United States

Ownership: Private

Established: 1884-01-01

Employees: 10K

Market Cap: -

Website: http://www.mskcc.org

Clinical Trials

A Study of Romosozumab in Women With Multiple Myeloma and Osteoporosis

Phase 1

Active, not recruiting

Conditions: Osteoporosis
Multiple Myeloma

Interventions: Drug: Romosozumab

First Posted Date: 2023-03-20

Last Posted Date: 2024-12-16

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 10

Registration Number: NCT05775094

Locations: 🇺🇸
Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities), Basking Ridge, New Jersey, United States
🇺🇸
Memorial Sloan Kettering Monmouth (Limited Protocol Activities), Middletown, New Jersey, United States
🇺🇸
Memorial Sloan Kettering Bergen (Limited Protocol Activities), Montvale, New Jersey, United States

and more 4 locations

Taxi ROADmAP (Realizing Optimization Around Diet And Physical Activity)

Phase 2

Recruiting

Conditions: Overweight
Overweight or Obesity
Obesity
Obese
Overweight and Obesity

Interventions: Behavioral: Counseling
Behavioral: Text Messages
Behavioral: Phone calls
Behavioral: Self-monitoring tools

First Posted Date: 2023-03-15

Last Posted Date: 2025-06-06

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 1785

Registration Number: NCT05770570

Locations: 🇺🇸
Mexican Consulate's Ventanilla de Salud (VDS), New York, New York, United States

A Study of Tumor-Treating Fields (TTFields) in People With Lung Adenocarcinoma

Phase 1

Recruiting

Conditions: Adenocarcinoma of Lung

Interventions: Device: NovoTTF-200T System

First Posted Date: 2023-03-13

Last Posted Date: 2024-06-24

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 25

Registration Number: NCT05764954

Locations: 🇺🇸
Memorial Sloan Kettering Nassau (Consent Only), Uniondale, New York, United States
🇺🇸
Memorial Sloan Kettering Westchester (Consent Only), Harrison, New York, United States
🇺🇸
Memorial Sloan Kettering Bergen (Consent Only), Montvale, New Jersey, United States

and more 4 locations

Study of 19(T2)28z1xx TRAC-Chimeric Antigen Receptor (CAR) T Cells in People With B-Cell Lymphoma

Phase 1

Active, not recruiting

Conditions: B-Cell Lymphoma
DLBCL, Nos Genetic Subtypes
Large B-cell Lymphoma
High-grade B Cell Lymphoma
Mediastinal Large B-cell Lymphoma

Interventions: Biological: 19(T2)28z1xx TRAC T cell

First Posted Date: 2023-03-07

Last Posted Date: 2025-04-23

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 30

Registration Number: NCT05757700

Locations: 🇺🇸
Memorial Sloan Kettering Cancer Center (All Protocol Activities), New York, New York, United States

A Study of Gilteritinib in Combination With Ivosidenib or Enasidenib in People With Acute Myeloid Leukemia (AML)

Phase 1

Recruiting

Conditions: Acute Myeloid Leukemia (AML)

Interventions: Drug: Gilteritinib
Drug: Ivosidenib
Drug: Enasidenib

First Posted Date: 2023-03-06

Last Posted Date: 2025-03-05

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 36

Registration Number: NCT05756777

Locations: 🇺🇸
Memorial Sloan Kettering Basking Ridge, Basking Ridge, New Jersey, United States
🇺🇸
Memorial Sloan Kettering Monmouth, Middletown, New Jersey, United States
🇺🇸
Memorial Sloan Kettering Bergen, Montvale, New Jersey, United States

and more 4 locations

Study of Peripheral Arterial Disease (PAD) in People With Cancer Who Will Be Having Surgery

Recruiting

Conditions: Peripheral Arterial Disease (PAD) in Cancer Patients

Interventions: Diagnostic Test: ABI/TBI
Other: Questionnaires

First Posted Date: 2023-03-06

Last Posted Date: 2025-03-04

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 500

Registration Number: NCT05754944

Locations: 🇺🇸
Memorial Sloan Kettering Cancer Center (All Protocol Activities), New York, New York, United States

A Study on the Effects of Exercise Therapy on Signs of Prostate Cancer

Phase 2

Recruiting

Conditions: Prostate Cancer
Prostate Adenocarcinoma
Localized Prostate Carcinoma

Interventions: Behavioral: Exercise Therapy

First Posted Date: 2023-03-02

Last Posted Date: 2025-04-23

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 102

Registration Number: NCT05751434

Locations: 🇺🇸
University of California, Los Angeles (Data and Specimen Analysis Only), Los Angeles, California, United States
🇺🇸
Hartford Healthcare Alliance (Data collection only), Hartford, Connecticut, United States
🇺🇸
Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities), Basking Ridge, New Jersey, United States

and more 6 locations

A Study of ADCLEC.syn1 in People With Acute Myeloid Leukemia

Phase 1

Recruiting

Conditions: Acute Myeloid Leukemia

Interventions: Biological: ADCLEC.syn1 CAR T cells
Drug: Conditioning chemotherapy

First Posted Date: 2023-02-28

Last Posted Date: 2025-04-15

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 40

Registration Number: NCT05748197

Locations: 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States
🇺🇸
Memorial Sloan Kettering Westchester (Limited Protocol Activities), Harrison, New York, United States
🇺🇸
Memorial Sloan Kettering Cancer Commack - Suffolk (Limited Protocol Activities), Commack, New York, United States

and more 4 locations

PET Imaging Using 64Cu-Tz-SarAr and hu5B1-TCO in People With Pancreatic, Colorectal, Bladder Cancer or Cancers With Elevated CA19.9

Phase 1

Recruiting

Conditions: Pancreatic Ductal Adenocarcinoma
Metastatic Pancreatic Ductal Adenocarcinoma
Primary Pancreatic Ductal Adenocarcinoma
Pancreatic Cancer
Metastatic Pancreatic Cancer

Interventions: Diagnostic Test: PET Scan
Drug: hu5B1-TCO
Drug: 64Cu-Tz-SarAr
Diagnostic Test: Pharmacokinetics

First Posted Date: 2023-02-21

Last Posted Date: 2025-05-16

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 22

Registration Number: NCT05737615

Locations: 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States

A Study of Immune Suppression Treatment for People With Sickle Cell Disease or β-Thalassemia Who Are Going to Receive an Allogeneic Hematopoietic Cell Transplantation (HCT)

Phase 2

Recruiting

Conditions: Thalassemia
Sickle Cell Disease
Thalassemia, Beta

Interventions: Drug: Fludarabine
Drug: Cyclophosphamide
Drug: Tacrolimus
Drug: Mycophenolate Mofetil
Biological: Rabbit ATG
Drug: Dexamethasone
Drug: Bortezomib
Drug: Rituximab

First Posted Date: 2023-02-21

Last Posted Date: 2025-05-20

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 24

Registration Number: NCT05736419

Locations: 🇺🇸
Memorial Sloan Kettering Bergen (Consent only), Montvale, New Jersey, United States
🇺🇸
Memorial Sloan Kettering Monmouth (Consent only), Middletown, New Jersey, United States
🇺🇸
Memorial Sloan Kettering at Basking Ridge (Consent only), Basking Ridge, New Jersey, United States

and more 3 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy